Skip to Main Content

Rise and shine, everyone, another busy day is on the way. Although the days may seem to blur together, we can tell there is much to do as our calendar for all sorts of calls gets crowded and reading material piles up. And in times like these, busy is a good thing, yes? To keep the neurons working, we are firing up the coffee kettle for another cup of stimulation. Caramel vanilla cream is the choice today. Please feel free to join us. Meanwhile, here are a few items of interest. Hope your day is successful and safe. …

Seeking to blunt concerns about access to its remdesivir treatment for Covid-19, Gilead Sciences (GILD) signed deals with five generic companies in India and Pakistan to manufacture and distribute the experimental medicine to 127 countries, STAT says. Under the agreements, the companies can set their own prices, but will not have to pay royalties to Gilead until the World Health Organization declares an end to the public health emergency for the novel coronavirus, or until another medicine or vaccine is approved to treat or prevent Covid-19.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!